Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

SOUTH SAN FRANCISCO, CA, USA I April 07, 2025 I ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which includes a workforce reduction of over 30%. The Company estimates that it will ...

Patients with lung adenocarcinoma carry a specific mutation in the Epidermal Growth Receptor Factor (EGFR) gene, and are treated with a class of targeted drugs called “EGFR tyrosine kinase inhibitors" ...

The DUSP22 gene encodes dual specificity protein phosphatase 22, an enzyme that plays a key role in regulating epidermal growth factor receptors (EGFR) and the downstream extracellular ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD ... frequently associated with mutations in EGFR, KRAS, ALK, and BRAF, while LUSC is ...